Currently, therapeutic development in FSHD largely focuses on inhibition of DUX4 expression with the aim of minimizing the pro-apoptotic effect of DUX4 target gene expression, and several molecules are in development with efficacy currently unclear (31,32,38–42). This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.